For most people prescribed hydroxyurea, the drug can be taken indefinitely with proper monitoring. Follow-up data spanning nearly two decades in sickle cell disease patients show not only sustained safety but actually reduced mortality with long-term use, and similar durability has been observed in patients with blood cancers like polycythemia vera and essential thrombocythemia. That said, “safely” does real work in that sentence. Hydroxyurea demands regular blood tests, dose adjustments, and vigilance for a handful of side effects that can emerge months or years into treatment. The question is less about a fixed expiration date and more about whether you and your care team are catching problems early enough to manage them.
What Hydroxyurea Does and Why Duration Matters
Hydroxyurea was originally developed as a cancer drug. It works by shutting down an enzyme cells need to copy their DNA, which slows the production of rapidly dividing cells. That mechanism makes it useful in myeloproliferative neoplasms, where the bone marrow overproduces blood cells, and it also happens to boost fetal hemoglobin in people with sickle cell disease, reducing the frequency of painful crises by roughly half.1PubMed Central. Hydroxyurea in sickle cell disease: drug review Because none of these conditions are curable with hydroxyurea alone, the expectation from the start is that patients will take it for years, possibly for life. That makes long-term safety data especially important.
The Longest Safety Data in Sickle Cell Disease
The strongest evidence for long-term safety comes from follow-up studies of patients originally enrolled in a landmark randomized trial in the 1990s. After 17.5 years of observation, researchers found that people with extended hydroxyurea exposure had significantly better survival than those who never took it or took it for fewer than five years. The overall death rate in the study group was high, which reflects the severity of sickle cell disease itself, but long-term hydroxyurea users were clearly dying less often. Pulmonary complications accounted for about a quarter of deaths, and the overwhelming majority of those deaths occurred in people who had little or no hydroxyurea exposure.2American Journal of Hematology. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up An earlier analysis at the nine-year mark had already shown a roughly 40% reduction in mortality among hydroxyurea users.3JAMA. Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment
In children, the picture looks even more reassuring. A cohort of infants started on hydroxyurea and followed continuously for fifteen years showed sustained blood-count improvements the entire time, with no malignancies, no strokes, and no deaths. Growth stayed at the 50th percentile for height and weight, puberty arrived on schedule, and all participants were at grade level in school.4PubMed Central. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia A separate study of infants treated for four years confirmed fewer acute chest syndrome episodes and possibly preserved organ function compared to historical controls.5PubMed Central. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study These are small studies, but the consistency of the findings across age groups and durations is genuinely encouraging.
Long-Term Use in Blood Cancers
In myeloproliferative neoplasms like essential thrombocythemia and polycythemia vera, hydroxyurea is often the first-line treatment. A pivotal trial in high-risk essential thrombocythemia patients showed that hydroxyurea dramatically cut the rate of dangerous blood clots compared to no treatment, with only about 4% of the treated group experiencing a thrombotic event versus 24% of controls.6PubMed. Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis Many of these patients remain on hydroxyurea for years or decades, and the drug continues to be a cornerstone of management precisely because it has an acceptable long-term profile in this population.
The main worry with indefinite use in blood cancers has historically been whether hydroxyurea itself causes leukemia. This concern gets its own section below, but the short version is that large studies have not found a statistically significant increase in leukemic transformation attributable to hydroxyurea, as opposed to the underlying disease’s own tendency to progress.
Does Hydroxyurea Cause Cancer Over Time?
This is probably the single most common fear among long-term users, and it deserves a careful answer. Because hydroxyurea interferes with DNA replication, the theoretical worry is that years of exposure could damage cells in ways that promote malignancy. In practice, the evidence is more reassuring than alarming, though not perfectly clean.
In myeloproliferative neoplasms, a large case-control study examined leukemia risk at increasing cumulative doses of hydroxyurea. At every dose tier, the odds ratios for developing leukemia or myelodysplastic syndrome were close to 1.0 and not statistically significant. The study concluded that the risk of leukemic transformation was significantly associated with other older treatments like radioactive phosphorus and alkylating agents, but not with hydroxyurea.7PubMed Central. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms Another analysis of patients with polycythemia vera, essential thrombocythemia, and myelofibrosis came to the same conclusion, finding no statistical association between hydroxyurea therapy and transformation to leukemia.8American Journal of Hematology. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
That said, individual case reports do exist. One described a young sickle cell patient who developed acute myeloid leukemia after about two years of hydroxyurea, with genetic findings suggesting a treatment-related cause.9PubMed Central. Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient Case reports like these keep the question alive, but they stand against population-level data that shows no clear signal. The honest summary: hydroxyurea has not been proven to increase leukemia risk in large studies, but the theoretical basis for concern is real enough that clinicians watch for it.
Skin cancer is a separate story. A growing body of evidence links long-term hydroxyurea use to nonmelanoma skin cancers, particularly in patients with myeloproliferative disorders.10PubMed. Nonmelanoma skin cancer associated with Hydroxyurea treatment: Overview of the literature and our own experience The risk appears to be higher in fair-skinned patients and those with significant sun exposure. If you are on hydroxyurea long-term, regular skin checks are a reasonable precaution, especially if you are also older or have a history of skin lesions.
Side Effects That Show Up With Extended Use
Many of hydroxyurea’s side effects are things you would notice relatively early, within the first weeks or months, but a few are specifically long-duration problems. Leg ulcers are probably the most distinctive. In one study of 41 cases, ulcers developed after prolonged treatment and were often accompanied by other skin changes like nail discoloration and skin thinning. The good news is that about 80% of patients saw complete healing once hydroxyurea was stopped, typically within a few months.11JAMA Dermatology. Leg Ulcers and Hydroxyurea: Forty-one Cases These ulcers are painful and slow to heal, and they are one of the recognized reasons clinicians switch patients to alternative treatments.
Lung toxicity is rarer but more serious. There have been reports of patients developing lung fibrosis or a pattern resembling hypersensitivity pneumonitis after hydroxyurea exposure.12PubMed Central. Fibrotic Lung Toxicity Induced by Hydroxycarbamide This appears to be uncommon, but it underscores why unexplained shortness of breath in someone on hydroxyurea should prompt a workup.
Why Blood Monitoring Cannot Be Skipped
Hydroxyurea’s whole point is to suppress bone marrow activity, so it is not surprising that the marrow can be suppressed too far. The most predictable serious complication is a dangerous drop in blood cell counts, a condition called pancytopenia. This is usually reversible when you stop the drug temporarily, but it can become life-threatening if it is not caught. The risk is amplified in people with kidney disease, because the kidneys are the main route for clearing hydroxyurea from the body. Impaired kidneys mean the drug hangs around longer and builds up to higher levels.13PubMed Central. A predictable but life-threatening complication of hydroxyurea in a patient with sickle cell anaemia
Pharmacokinetic studies confirm that kidney function is a major driver of how much drug ends up in your system. Patients with reduced kidney function have measurably higher drug exposure at the same dose, and researchers have suggested starting at a lower dose for those with significant kidney impairment.14PubMed. The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease Even in patients with normal kidneys, kidney function and body weight together account for nearly half of the variation in drug levels from person to person.15PubMed. Impact of renal function on hydroxyurea exposure in sickle-cell disease patients In children, body weight and a kidney function marker called cystatin C are the most important factors guiding dose selection.16PubMed Central. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia
All of this means that regular blood tests are not optional. One quality-improvement study found that when sickle cell patients moved from sporadic monitoring to a structured clinic with frequent lab checks, the average number of blood tests per patient per year jumped from fewer than two to more than seven. That increase in monitoring led to more dose adjustments and measurably better hemoglobin markers.17BMJ Open Quality. Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea In the early months of treatment, blood counts are typically checked every two to four weeks. Once a stable dose is established, the interval can stretch to every two or three months, but it should never drop to zero.
Fertility and Pregnancy Concerns
This is a topic that affects decisions about how long to stay on the drug, particularly for men and women of reproductive age. For men, the news is sobering. A systematic review and meta-analysis found that hydroxyurea significantly lowers sperm concentration and total sperm count, and these reductions persisted even after stopping treatment.18PubMed Central. Effects of hydroxyurea on fertility in male and female sickle cell disease patients. A systemic review and meta-analysis Smaller studies tell a consistent story: most men on hydroxyurea have abnormal sperm parameters, and while stopping the drug sometimes allows partial recovery, morphology and motility often stay impaired.19PubMed. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease One study found that in men who had been on treatment, most still had abnormal sperm parameters years later.20Haematologica. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males Men who want to have children should discuss sperm banking before starting or continuing long-term hydroxyurea.
For women, the picture is more nuanced. Hydroxyurea is classified as a drug that should be avoided during pregnancy because of animal data showing birth defects at high doses. In human studies, however, the findings are less alarming than the warning label suggests. A large observational analysis found that using hydroxyurea at the time of conception only did not significantly increase the risk of miscarriage or birth problems. But continued use through pregnancy was associated with roughly double the odds of miscarriage or stillbirth, and an increased chance of low birth weight in full-term babies.21PubMed Central. Pregnancy Outcomes with Hydroxyurea Use in Women with Sickle Cell Disease A systematic review of case reports found that neither birth defects nor blood-count problems in newborns were consistently seen, even when mothers had some hydroxyurea exposure during pregnancy.22Journal of Obstetrics and Gynaecology Canada. Safety of Hydroxyurea in Pregnancy: A Systematic Review of the Literature The general advice is to stop hydroxyurea before a planned pregnancy if possible, but accidental early exposure is not considered grounds for panic.
When Your Doctor Might Switch You Off Hydroxyurea
There are formal criteria for what counts as hydroxyurea failure, particularly in polycythemia vera. European guidelines define resistance as, for example, still needing blood draws to keep blood thickness under control after three months at full dose, or having blood counts that stay dangerously high despite maximum therapy. Intolerance is defined by side effects that are serious enough to warrant stopping, including leg ulcers, mouth sores, gastrointestinal symptoms, lung inflammation, or fevers at any dose.23PubMed Central. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices
For patients who cannot continue hydroxyurea, alternatives exist but vary by condition. In myeloproliferative neoplasms, JAK inhibitors have shown strong activity against symptoms like fatigue, itching, and enlarged spleen that hydroxyurea could not control.24PubMed. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms In sickle cell disease, newer drugs like voxelotor and crizanlizumab target different aspects of the disease. For some patients, particularly children and young adults with severe disease, stem cell transplant can be curative and removes the need for hydroxyurea entirely.
Drug Interactions That Change the Safety Calculation
Hydroxyurea’s bone marrow suppression can become much more dangerous when combined with other drugs that also suppress blood cell production. One study of patients receiving hydroxyurea alongside imatinib for brain tumors found that a quarter developed severe blood-count drops. In one case, the toxicity persisted for months after both drugs were stopped and contributed to the patient’s death.25PubMed. Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas This is an extreme example from an oncology setting, but the principle applies broadly: any drug that independently suppresses the marrow can amplify hydroxyurea’s main toxicity. If you are on hydroxyurea and start a new medication, your doctor should be checking whether overlapping marrow suppression is a concern.
How Sticking With It Affects Quality of Life
The practical question behind “how long can I take this?” is often really “is it worth staying on this?” Quality-of-life data offer a partial answer. A systematic review found that higher adherence to hydroxyurea was associated with less pain, fewer pain crises, less fatigue, and better physical function and mobility. The benefits extended to mental health as well, with lower anxiety and fewer depressive symptoms among patients who stuck with their regimen.26PubMed Central. Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review
The relationship between adherence and benefit is not straightforward, though. An earlier study found that quality-of-life improvements beyond pain reduction were limited to patients who achieved a strong fetal hemoglobin response. Patients who took the drug but did not get a good hemoglobin response saw benefits mainly in pain reduction and not much else.27PubMed Central. Hydroxyurea and sickle cell anemia: effect on quality of life This suggests that the degree of benefit is dose-dependent and biologically variable, which is one more reason regular lab monitoring matters. If your fetal hemoglobin is not rising despite good adherence, your dose may need adjustment or the drug may not be the right fit for you.
Adherence itself varies by age group. One study found that young adults with sickle cell disease actually had higher hydroxyurea adherence than children and adolescents, based on objective lab markers. Children and teens showed lower fetal hemoglobin percentages and higher white blood cell counts, both indicators that the drug was not being taken consistently.28PubMed Central. Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents For families managing a child’s sickle cell disease, this is worth knowing: the hardest years for adherence are the teenage years, and that is also when the consequences of lapsed treatment can start to accumulate.
What Happens When You Stop
For sickle cell patients, stopping hydroxyurea means the fetal hemoglobin boost goes away. Pain crises tend to return to pre-treatment frequency. The 17.5-year follow-up study made this starkly visible: the vast majority of pulmonary deaths occurred in people who had never taken hydroxyurea or had taken it for fewer than five years, while rates of stroke, organ dysfunction, and infection were similar across all groups regardless of treatment duration.29PubMed Central. The Risks and Benefits of Long-term Use of Hydroxyurea in Sickle Cell Anemia: A 17.5 Year Follow-Up In other words, the survival benefit appears to grow the longer you stay on it, and stopping forfeits that accumulated protection.
For myeloproliferative neoplasms, discontinuation is usually driven by side effects or resistance rather than a planned end date. If you stop because of leg ulcers, those typically heal within a few months. If you stop because of inadequate disease control, the transition to a second-line therapy needs to happen promptly, since uncontrolled blood counts carry their own serious risks of clotting and disease progression. There is no evidence that taking hydroxyurea for a certain number of years and then stopping provides lasting disease modification in these cancers; the benefit exists only while you are on the drug.
When Kidney Disease Changes the Equation
This deserves special emphasis because sickle cell disease itself frequently damages the kidneys over time, meaning many long-term hydroxyurea users will eventually develop some degree of kidney impairment. As kidney function declines, drug clearance slows and the risk of toxicity climbs. The standard starting dose may become dangerous in someone whose kidney function has deteriorated since they first began treatment. One pharmacokinetic study recommended cutting the initial dose to roughly half the standard amount for patients with significantly reduced kidney function.14PubMed. The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease The bone marrow suppression that is normally mild and manageable can become severe and prolonged in someone whose kidneys cannot clear the drug efficiently.13PubMed Central. A predictable but life-threatening complication of hydroxyurea in a patient with sickle cell anaemia If you have been on hydroxyurea for years and your kidney function is declining, ask whether your dose has been rechecked recently. It is one of the most predictable ways long-term use can turn from safe to dangerous.